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Background: Studies showing a high prevalence of low serum testosterone in men 
with type 2 diabetes mellitus (T2DM) are well documented but evidence from sub- 
Saharan Africa is scanty. 
Aim: To determine the prevalence and associated risk factors of low serum 
testosterone and the prevalence of androgen deficiency symptoms in South African 
men with T2DM 
Methods: A cross-sectional observational study was performed among men with 
T2DM attending two outpatient adult diabetes clinics in KwaZulu-Natal. Androgen 
deficiency symptoms were assessed using the Ageing Male’s Symptom Scale (AMS) 
questionnaire and direct enquiry. Serum total testosterone (TT), sex-hormone 
binding globulin (SHBG), luteinising hormone (LH), HbA1c, fructosamine, serum lipids 
were measured and free-testosterone (FT) was calculated. TT, SHBG and FT levels 
were measured in control subjects with no history of diabetes. 
Results: The study included 148 men with T2DM (Study Group) and 50 control 
subjects (Control Group). The mean age of the control group was 43.9 ± 10.7 years 
and the mean BMI was 27.11 ± 4.2 kg/m2. In the study group, the majority were 
African (Black) (58.7%); Indians (39.2%) and Whites (2.1%) constituted the 
remainder. Mean age was 57.5 ± 11.2 years; mean duration of diabetes 11.4 ± 8.9 
years; mean HbA1c was 8.6 ± 1.9%. Metabolic syndrome was found in 86.4% (n:127) 
of the Study group. Mean TT, SHBG, FT and median LH (IQR) in the Study group 
were within normal range (14.5 ± 5.8 nmol/l, 40.7 ± 20.3 nmol/l, 265.9 ± 90.4 pmol/l 
and 5.3 [3.8-7.3] IU/l, respectively). However, mean serum TT and FT was lower in 
the Study group than Control subjects (14.5 ± 5.8 vs. 18.8 ± 7.2 nmol/l, p <0.001 and 







The prevalence of LSTT and LSFT was 35.8% and 16.2%, respectively. Prevalence 
of LSFT increased with age and higher body mass index (BMI) categories with the 
highest rate noted in >40 kg/m2 BMI category (50%). 
In multivariate analysis, LSFT was significantly associated with age [OR 1.05 (95% 
CI 1.02-1.218), p=0.043] and waist circumference (WC) [OR 1.033 (95% CI 0.999- 
1.068), p=0.059]. LSTT was associated with BMI only [OR 1.138 (95%CI 1.063- 
1.218), p<0.0001]. TT correlated inversely with BMI, WC and the number of 
metabolic syndrome criteria. FT correlated inversely with BMI, WC and WHR. For 
both FT and TT, no significant correlation was observed with HbA1c. 
The prevalence of androgen deficiency symptoms using AMS score was 74.5%. The 
prevalence of any androgen deficiency symptom on direct enquiry was 68.9%. The 
AMS score correlated poorly with LSTT or LSFT and was not superior to direct 
enquiry. 
Conclusion: In this group of predominantly African and Indian men with T2DM from 
KwaZulu-Natal, there was a high prevalence of LSTT and LSFT. Serum TT and FT 
was lower in men with T2DM compared to control subjects. Waist circumference was 
a significant risk factor associated with LSFT while LSTT was associated with higher 
BMI and older age. There was a high prevalence of androgen deficiency symptoms 
using both the AMS score and on direct enquiry. The AMS score was a poor 
predictor of low testosterone and was not superior to direct enquiry. More research is 
required locally and from other sub-Saharan African countries before routine 







CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
The global prevalence of type 2 diabetes mellitus (T2DM) is escalating at an 
alarming pace with the International Diabetes Federation projecting that 642 million 
people will be affected by 2040 (1). In Africa alone, there will be more than a 
doubling in the total number of people living with diabetes between 2015 and 2040. 
This trend appears to mirror that being witnessed worldwide with respect to the 
global obesity epidemic. South Africa is not immune to this trend and is estimated to 
have among the highest rates of overweight in sub-Saharan Africa (SSA). The 
reported prevalence of obesity among South African women is 42%, while the 
prevalence of both overweight and obesity is 69.3%. Among men, the prevalence of 
overweight or obesity is reportedly 39%, with 14% being obese (2). Therefore South 
Africa ranks among the top obese nations of the world, with the associated negative 




Male androgen deficiency is an international health-related issue that has received 
increased attention over the past two decades and has generated a number of trials 
in men with diabetes. The prevalence of androgen deficiency in middle-aged and 
older men was found to be between 6 and 12% in the Massachusetts Male Aging 
Study (4). Testosterone deficiency has been associated with a plethora of disorders 
including T2DM, obesity, cardiovascular disease and the metabolic syndrome. The 
reported prevalence of low testosterone levels among men with T2DM is high and 
ranges between 30% and 50% (5,6). The significance of this association with T2DM 
has long been debated with many experts arguing that low total testosterone levels 
are a consequence of a low sex-hormone binding globulin (SHBG) level which in 
turn is related to insulin resistance. However, this argument is unlikely to completely 







demonstrated with free testosterone levels. The aetiology for this association 
remains uncertain, but it has been postulated that a hypothalamic or pituitary cause 
is likely, given the predominant finding of normal or low luteinizing hormone (LH) 
levels with low testosterone levels (6). International guidelines advocate screening 
with a total testosterone assay, but recommend measuring SHBG and calculating 
free testosterone levels in patients with total testosterone levels near the lower limit 




Defining low testosterone levels 
 
The finding of a low testosterone level alone does not imply hypogonadism or signify 
a clinical disease entity. Rather, a diagnosis of hypogonadism requires an 
unequivocally low testosterone level in conjunction with typical signs or symptoms of 
hypogonadism (6). Therefore it would be important to elicit symptoms of androgen 
deficiency from men with T2DM. Such symptoms include loss of libido, loss of 
energy, erectile dysfunction, hot flushes and reduced stamina. In this regard, a 
number of screening tools in the form of self-administered questionnaires have been 
developed to assess for the symptoms of androgen deficiency and its severity. 
These include the Ageing Male’s Symptom Scale (AMS), Massachusetts Male Aging 
Study (MMAS) questionnaire and Androgen Deficiency in the Ageing Male 
Questionnaire (ADAM) (7). Although the benefits of employing these questionnaires 
in diabetic men may seem logical, none of the available questionnaires are sensitive 
or specific enough to be able to make a conclusive diagnosis of hypogonadism. 
Also, there is currently insufficient proof to support their routine use in clinical 
practice. Furthermore, none of these screening questionnaires have been validated 
in African men. Despite this lack of information, many physicians continue to use 










Furthermore, the actual laboratory definition of a low testosterone level is itself 
controversial for a number of reasons and therefore presents a dilemma to those 
wanting to easily diagnose the condition. At the core of the argument is the absence 
of any classical sign or symptom of testosterone deficiency or any definitive injurious 
clinical consequences associated with a particular lower limit of serum testosterone. 
Moreover, there are notable variations in the normal reference ranges of serum 
testosterone level between laboratories. Consequently, there is no concordance with 
respect to the definition of a low testosterone level among healthcare practitioners as 
well as between laboratories. Even more controversial is the derivation of the 
currently accepted “normal” assay range for serum total testosterone used by 
laboratories which are generally obtained using convenience sampling, usually from 
small groups which may have an over-representation of older men. It is therefore 
questionable whether this range is representative of the sexual and physical health 
in the general population of men. Ideally, normal ranges should be age and 
population specific with individual reference ranges derived from healthy controls for 




In 2009, a Consensus Statement on the treatment and monitoring of late onset 
hypogonadism in males was issued jointly by the International Society of Andrology 
(ISA), the International Society for Study of the Aging Male (ISSAM), the European 
Association of Urology (EAU), the European Association of Andrology (EAA) and the 
American Society of Andrology (ASA)(8). This consensus recommended that total 
testosterone (TT) levels above 12nmol/l do not require treatment, and levels below 
8nmol/l (with symptoms) may require testosterone replacement therapy. For levels 
between 8-12nmol/l, the consensus statement recommended repeating TT and 







recommended that total low testosterone be defined using the lower limit of normal 
range for healthy young men established in the laboratory performing the assay (4). 
However, there are no generally accepted lower limits of normal FT for the diagnosis 
of hypogonadism. If the evidence for an association between TT and typical 
symptoms of androgen deficiency is weak, then the relationship is even weaker with 
FT. Since the measurement of TT is clearly more economical, it remains the test 




Circulating total and free testosterone 
 
Testosterone is the male hormone synthesized primarily by the Leydig cells in 
response to stimulation of the testes by luteinizing hormone. Once secreted into the 
circulation, it may exist either in a free state or bound to plasma proteins. 
Testosterone may circulate bound to SHBG (44%), cortisol binding globulin (4%) or 
albumin (50%) and about 2-3% actually remains unbound. Testosterone is loosely 
bound to albumin and the term “bioavailable testosterone” is used to describe the 
sum of free and albumin-bound testosterone. Since testosterone is to a large degree 
bound to SHBG, the measurement of TT is greatly influenced by changes in SHBG 
level. Conditions that increase serum SHBG and hence TT include ageing, liver 
cirrhosis, hepatitis, thyrotoxicosis, oestrogen therapy, anticonvulsant use and human 
immunodeficiency virus (HIV) infection. In contrast, serum SHBG may decline with 
obesity, T2DM, nephrotic syndrome, hypothyroidism, acromegaly or with the use of 




Laboratory measurement of testosterone 
Serum TT remains the test recommended by most endocrine societies and 







research data when compared to FT. Results of laboratory measurement of TT can 
be significantly influenced by the type of assay method employed. The most 
accurate measurement of testosterone status remains equilibrium dialysis, but this is 
labour intensive and costly. Older assay methods employed radioimmunoassay 
(RIA) which is based on competitive binding of testosterone in serum to a 
testosterone specific antibody after pre-exposure to a fixed amount of radioactive 
labelled tracer. Most laboratories employ the ELISA (enzyme linked immunosorbent 
assay) technique which is based on the same principle of competitive binding of 
testosterone used in the RIA with the exception that a non-radioactive tracer and a 
fixed amount of testosterone antibodies are employed with the ELISA method. More 
accurate assay methods include liquid chromatography tandem mass spectrometry 
(LCMS/MS) which are more expensive and often used in research settings but are 





Low serum testosterone and ageing 
 
There is considerable epidemiologic evidence demonstrating a decline in 
testosterone levels with ageing. In the Baltimore Longitudinal Study of Aging (BLSA) 
cohort made up of 3,565 middle-class, mostly Caucasian men in the United States, 
the incidence of LSTT increased from 20% of men aged over 60 years, 30% over 70 
years, to 50% over 80 years-of-age (9). The Massachusetts Male Aging Study 
(MMAS) showed a similar high prevalence among a cohort of 415 healthy men and 
1294 men with chronic disease aged between 40 and 70 years (10). Age related 
decline in testosterone levels, often referred to as late onset hypogonadism (LOH) is 
also referred to as andropause or androgen deficiency of the ageing male (ADAM). 
LOH is defined as a clinical and biochemical syndrome associated with advancing 







The effects of LOH may include erectile dysfunction, loss of libido, loss of muscle 
mass and increased abdominal adiposity. LOH has also been associated with 




Relationship between low serum testosterone and type 2 diabetes mellitus 
 
The reported prevalence of low testosterone levels among male subjects with T2DM 
is high and ranges between 30% and 50% (5,6). This evidence comes mainly from 
small population based studies but is also supported by at least two large meta- 
analyses (11,12). Using multiple regression models, after adjusting for age and body 
mass index (BMI), T2DM was still associated with lower total testosterone (TT) 
levels; there seems to be an inverse relationship between TT and T2DM (11) . 
Conversely, longitudinal studies have also shown that men with higher testosterone 
levels have a lower risk of developing type 2 diabetes (11,12). A single study from 
South Africa showed a high prevalence (50%) of low serum testosterone among 
men with diabetes attending a tertiary diabetes clinic at an academic centre in 
Pretoria. Despite the available evidence, current international diabetes guidelines do 
not advocate routine screening for testosterone levels among male patients with 
diabetes. Longitudinal studies have also reported lower TT levels among men with 
metabolic syndrome compared to controls. More prospective studies are required to 




Aetiology of low serum testosterone in men with diabetes 
 
There is no clear explanation for the recognised association but a number of theories 
have been proposed which in large part are linked to obesity. For example, adipose 
tissue related elaboration of inflammatory cytokines (adipokines) may have a 







hypogonadotropic hypogonadism (13). Furthermore, obesity per se is associated 
with lower SHBG levels and this may impact on the measurement of TT. It has also 
been postulated that LST in T2DM is related to chronic illness similar to that 




Testosterone and glucose metabolism 
 
Although some studies have shown an association between low testosterone levels 
and glucose metabolism including a higher HbA1c, it is unclear if therapy with 
testosterone will yield any significant gains in glycaemic control or insulin sensitivity. 
Studies in which replacement therapy has been used for testosterone deficiency 
have thus far shown conflicting results with some showing no changes in metabolic 
parameters such as glucose, lipids and HbA1c (15). Further large-scale studies are 
needed to investigate the potential for long term benefits regarding the treatment of 




Influence of Ethnicity on testosterone levels 
 
There are few studies that have shown ethnic differences in the levels of serum 
testosterone. A study from the United States showed that whilst TT, estradiol and 
SHBG did not differ between black and white men, after adjustment for age, black 
men had a modest but significant 2.5 to 4.9% higher FT level than white men (14). 
Suggested reasons for these findings include variances in steroid metabolism, 
geographic or environmental factors, disparity in body composition and genetic 
differences such as polymorphisms in the androgen receptor gene and length of the 







Data from sub-Saharan Africa 
 
There is a dearth of information on the prevalence of androgen deficiency symptoms 
and low serum testosterone levels in men with T2DM, from sub-Saharan Africa 
(SSA). To date published data is only available from only three countries, including 
Nigeria, Ghana and South Africa (16–20). These studies have shown high 
prevalence of low serum testosterone levels ranging from 29.5-50%. Available data 
from South Africa is limited to a single study from an academic centre in Pretoria 
(16). Furthermore, only a few studies have actually investigated the risk factors that 




Rationale for the study 
 
There is scanty information from South Africa regarding the prevalence of low serum 
testosterone levels among male subjects with T2DM. This study was therefore 
designed to determine the prevalence and associated risk factors of low serum 







CHAPTER 2: AIMS AND OBJECTIVES 
 
2.1 Study Aim 
 
To determine the prevalence and associated risk factors of low serum testosterone 
levels in South African men with type 2 diabetes mellitus attending two outpatient 




2.2 Study Objectives 
Primary Objective: 
To determine the prevalence of a low serum testosterone level among male patients 






a) To determine the prevalence of symptoms of androgen deficiency 
 
b) To determine the serum luteinizing hormone level among patients with low serum 
testosterone levels 







The hypothesis is that the prevalence of testosterone deficiency in South African 








CHAPTER 3: RESEARCH DESIGN AND METHODS 
 
3.1 STUDY DESIGN 
 





3.2. STUDY POPULATION 
 
3.2.1 Study Subjects 
 
All male patients attending the adult diabetes clinic at Inkosi Albert Luthuli Central 
Hospital (IALCH) or the medical outpatient diabetes clinic at Prince Mshiyeni 
Memorial Hospital (PMMH) were invited to participate in this study. The nature of the 
study and its aims were explained to the patients and participation was completely 







• Adult male patients aged over 18 years with a diagnosis of T2DM according 
to the World Health Organisation (WHO) definition 






• Unwillingness to participate 
 
• Diabetes classified other than type 2 diabetes 
 







3.2.2 Control Subjects 
 
Source of control subjects: 
 
Control subjects included healthy adult men employed at either IALCH or PMMH, 
Durban or relatives of patients attending the diabetes clinic. Potential for bias was 
minimised by excluding patients with a history of glucose intolerance, low 






• Age ≥18 years 
 






• Unwillingness to participate 
 
• Known to have testosterone deficiency (hypogonadism) or disorder of 
sexual development 






The sample size was based on the prevalence of low serum testosterone levels in 
men. Assuming a ratio of unmatched cases to controls of 1:1, to detect a 20% 
difference between diabetic and non-diabetic men at 95% confidence interval and 
80% power, the estimated sample size was 49 participants in each arm; total sample 











3.3 STUDY METHODS 
 
For all study subjects, information was collected at study entry and is outlined in the 
data sheet (Appendix 1) and included the following: 
3.3.1 History 
 
3.3.2 Clinical examination 
 







A detailed history was obtained from all subjects at entry into the study. This was 
obtained at the first interview via direct patient enquiry and patient folder review, and 
included the following: 








• date of diagnosis 
 
• duration (number of years) 
 
• microvascular complications (type) 
 
• macrovascular complications (type) 
 
(c) Past medical history 
 







• current or past treatment with testosterone of testosterone ester 
 
• current or past exposure to anabolic steroids 
 
• radiotherapy, chemotherapy, testicular torsion 
 
• orchidopexy or orchidectomy 
 
• previous orchitis eg mumps or TB 
 
• trauma to testes eg crush injury to pelvis and/or gonads 
 
• head trauma, neurosurgery to pituitary fossa 
 
(d) Current Drug therapy (including drug doses for antidiabetic therapy) 
 
(e) Smoking history 
 
(f) Enquiry of symptoms 
 
• change in growth of facial hair (beard growth) 
 
• loss of libido 
 
• erectile dysfunction 
 
(g) Patient questionnaire: Ageing Male’s Symptom (AMS) Questionnaire (7) in 
English and Zulu languages (Appendix 2 and Appendix 3) 
• Symptoms of androgen deficiency were assessed in all patients with the aid 
of the AMS questionnaire 
• Details of the patients’ responses to all 17 questions in the Ageing Male’s 
Symptom (AMS) questionnaire were captured 
• The AMS questionnaire includes 3 sub-categories consisting of a defined set 
of items 













Clinical examination was performed on all patients and recorded on the day of serum 





• Hip circumference 
 
• Waist circumference 
 




3.3.3 Laboratory Evaluation 
 
The following laboratory tests were performed on all patients included in the study: 
 
• serum total testosterone (TT) 
 
• serum sex-hormone binding globulin (SHBG) 
 
• free testosterone (FT) calculated, free androgen index (FAI) calculated 
 
• luteinizing hormone (LH) 
 
• gamma glutamyl transferase (GGT) 
 
• alkaline phosphatase (ALP), albumin, total protein 
 
• alanine transaminase (ALT), aspartate transaminase (AST) 
 
• total triglycerides, total cholesterol, LDL-cholesterol, HDL-cholesterol 
 
• glycated haemoglobin (HbA1c) and serum fructosamine 
 
• serum urea, electrolytes and creatinine 
 





Venous blood samples were collected from patients between 08h00 and 10h00. 







• 1 x 5ml Sodium fluoride containing tubes: plasma glucose 
 
• 2 x 10ml Plain tubes: serum lipids, serum urea, electrolytes and creatinine, 
serum liver function tests (LFT), fructosamine, total testosterone, SHBG, 
luteinising hormone 




All specimens for LH, SHBG, total and free testosterone were centrifuged and the 
plasma transferred to Eppendorf tubes for storage in a freezer at - 700C in the 
Department of Internal Medicine laboratory at Nelson R Mandela School of Medicine. 





Test: Method Platform 
HbA1c HPLC TOSOH G8 
Fructosamine Calorimetry Siemens Dimensions 
Lipid profile  Siemens Advia 1800 
Total testosterone Chemiluminescence Abbot architect 
Luteinizing hormone Chemiluminescence Abbott architect 
SHBG Chemiluminescence Abbott architect 
Free-testosterone Calculated Vermeulen formula * 






* Vermeulen formula: FT 5([T]2(N3 [FT]))/(Kt{SHBG 2 [T] 1 N[FT]}) (Eq IV), where Kt 
is the association constant of SHBG for T, and N 5 KaCa 1 1 
$ FAI formula: total testosterone (nmol/ L)) x 100 /sex hormone-binding globulin 
(SHBG) (nmol/ L) 











3.4.1 Low serum testosterone 
 
There is no accepted global definition for low serum total testosterone (LSTT). In this 
study LSTT was defined as a measured serum total-testosterone level below 12.0 
nmol/l (21). However, other levels of LSTT will also be determined: 
• LSTT < 8 nmol/l (21) 
 
• Borderline TT includes men with a TT that ranges between 8-12 nmol/l. 
 
Low serum free-testosterone (LSFT) was defined as a calculated free-testosterone 
level below the reference range for the laboratory (< 180 pmol/l) [lower limit of 
laboratory assay with a reference range of 180-739 pmol/l]. 
The Endocrine Society Clinical Practice Guideline definition of low testosterone 
includes patients with unequivocal LSTT and a LSFT in men with TT concentrations 
near the lower limit of the normal range [i.e. LSTT < 8 nmol/l and patients with TT 
between 8-12 nmol/l that have a FT<180 pmol/l (lower limit of laboratory assay with 




3.4.2 Androgen deficiency symptoms 
 
Patients with an AMS questionnaire score of ≥ 27 were defined as being consistent 
with LST and androgen deficiency. The classification of androgen deficiency 
symptoms (7) was based on the total score for each patient, as shown below: 
• < 26: no symptoms consistent with LST 
 
• 27-36: mild symptoms consistent with LST 
 













Hypogonadism was defined using serum free-testosterone and serum total- 
testosterone criteria. A diagnosis of hypogonadism was considered when low 
testosterone (total or free) has been documented in conjunction with symptoms of 
androgen deficiency (8). 
Using free-testosterone as the criterion, hypogonadism was defined as a low serum 
free-testosterone <180 pmol/l and a positive AMS score of 27 or more. 
Using total-testosterone as the criterion, hypogonadism was defined as a low serum 
total-testosterone < 12nmol/l (21) and a positive AMS score of 27 or more. Overt 
hypogonadism was defined as a total-testosterone <8 nmol/l and a positive AMS 
score of 27 or more. Possible hypogonadism was defined as a total-testosterone 




3.4.4 Classification of Luteinizing Hormone (LH) levels 
 
The laboratory reference range for LH levels vary between 3.8 mIU/L to 7.3mIU/L 
and values within this range were classified as normal. LH levels below 3.8 mIU/L 




3.4.5 Metabolic Syndrome 
 
Metabolic syndrome was defined by the criteria of the Joint Interim statement (22). 








• Elevated waist circumference (For Indian men ≥ 90cm; Indian women ≥ 
80cm; African men ≥ 94cm; African women ≥ 80cm) 
• Elevated triglycerides ≥ 1.7mmol/l (drug treatment for elevated triglycerides is 
an alternate indicator) 
• Reduced HDL-C <1.0 mmol/L in males; females <1.3 mmol/L (drug treatment 
for reduced HDL-C is an alternate Indicator) 
• Elevated blood pressure; systolic ≥ 130 mmHg and/or diastolic ≥ 85mmHg 
(anti-hypertensive drug treatment in a patient with a history of hypertension is 
an alternate indicator) 
• Elevated fasting blood glucose ≥ 5.6mmol/l (drug treatment of elevated 




3.5. Ethics statement 
 
The study was approved by the University of KwaZulu-Natal Biomedical Research 
Ethics Committee (BREC) and KwaZulu-Natal Department of Health (KZN DOH). 
BREC reference number: BF 225/13. Permission to conduct research was also 
obtained from IALCH and PMMH. Consent was obtained from each patient as 
required by hospital management, KwaZulu-Natal Department of Health, University 








3.6 Statistical Analysis 
 
The IBM Statistics Package for the Social Sciences (SPSS) version 23 was used to 
analyse the data. Descriptive analysis of the data was performed (means, standard 
deviations, ranges, frequencies and percentages). Independent t tests were used to 
compare continuous normal variables between binary groups. Pearson’s chi square 
tests were used to compare categorical variables between groups. Missing 
continuous data was replaced by the series mean. 
Univariate logistic regression analysis was used to screen all risk factors at the 0.1 
level of significance for inclusion into a multiple logistic regression model. Once 
predictors were chosen, they were entered into a backwards stepwise model with 
entry and exit probabilities set at 0.05 and 0.1 respectively. The final model is shown 
with odds ratio (OR) and 95% CI (confidence interval). Receiver operating 
characteristic (ROC) curves were used to calculate AUC (area under curve) and if 







CHAPTERS 4 - 12: RESULTS 
CHAPTER 4: CHARACTERISTICS OF THE TOTAL STUDY 
POPULATION 
The total study population included 148 male subjects with type 2 diabetes mellitus 
(Study Group) and 50 control subjects (Control Group) 
4.1 Study Group 
 
Of 157 patients who consented to participate in the study, 97 men were recruited at 
Inkosi Albert Luthuli Hospital and 60 men were recruited at Prince Mshiyeni 
Memorial hospital. A total of nine patients were excluded because they were known 
to have hypothalamic or pituitary disease. The study group for this analysis included 




4.1.1 Demographic and clinical characteristics 
 
Table 1 and Figure 1 shows the characteristics of the study group. The mean age of 
the study group was 57.5 ± 11.2 years. The majority were African (black) (58.7%) 
(n=87) followed by Indian patients (39.2%) (n=58); white patients were in the 
minority and constituted only 2.1% (n=3) of the study population. The mean duration 
of diabetes was 11.4 ± 8.9 years; almost half (47%) had diabetes duration > 10 
years. The overall prevalence of current cigarette smokers and ex-smokers was 





The prevalence of known diabetes related complications among study subjects is 







microalbuminuria and proteinuria were documented in 23.6%, 22.9% and 18.2% of 
patients, respectively. A past history of any known macrovascular disease was 
present in 22.2% of patients with the most common being ischaemic heart disease 
(IHD) (17.6%); peripheral vascular disease (PVD) and cerebrovascular disease 




Mean systolic and diastolic blood pressure was 136 ± 16.5 and 77.3 ± 10.0 mmHg, 
respectively. Anthropometric measures are shown in Table 1. The mean height and 
weight were 170 ± 0.06 cm and 85.9 ± 17.8 kg, respectively; mean BMI was 29.8 ± 
6.0 kg/m2. The mean waist circumference was 103.3 ± 12.9 cm and mean waist to 
hip ratio (WHR) was 0.97 ± 0.07. The majority of the patients were overweight or 
obese (81.8%) and only 18.2% had a BMI below 25 kg/m2 (Figure 2). Obesity was 
noted in 41.3% of patients with 18.2% being classed as morbid obesity. The 
prevalence of metabolic syndrome was 85.8%. All five criteria were present in 14% 





4.1.2 Medication history in the study group 
 
Medication history in the Study group is shown in Table 2. Regarding anti- 
hyperglycaemic therapy, 42.9% were on oral agents, 32.9% on combination oral and 
insulin therapy and 24.2% on insulin alone. Among those using oral agents alone or 
in combination with insulin, the majority of patients were treated with metformin 
(71.4%) (n=100); 31.4% (n=44) were on a sulphonylurea and 1% were treated with a 
dipeptidylpeptidase-4 (DPP4) inhibitor. The median daily metformin dose was 
2000mg. Among sulphonylurea users, glibenclamide was used in 9.3% (n=13) and 







12.5mg and 160mg, respectively. Over half the patients (55.7%) were on insulin 
therapy, either alone or in combination with oral agents. The median daily insulin 




Regarding non-glycaemic therapy, 65.7% (n=92) were on statin therapy and 3.6% 
(n=5) on fibrates. The majority (83.4%) were on anti-hypertensive agents and two- 
thirds on aspirin therapy. The most commonly prescribed anti-hypertensives were 
the angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor 
antagonists (ARB) (68.6%). Among anti-hypertensive therapy users, only 18.8% of 
patients were taking a single agent while the majority were on multiple agents 
(81.2%). Two anti-hypertensive agents were prescribed in 37.6% (n=44) of patients; 
three agents in 29.9% (n=35); four agents in 10.3% (n=12) and five agents were 




4.1.3 Laboratory test results in the Study Group 
 
The laboratory results for the Study group are shown in Table 3. The mean HbA1c 
was 8.6 ± 1.9 % and mean serum fructosamine, 317.5 ± 71.7 µmol/l. Mean serum 
total cholesterol was 4.2 ± 1.3 mmol/l, mean serum HDL cholesterol 1.1 ± 0.3 
mmol/l, mean serum LDL cholesterol 2.5 ± 1.41 mmol/l and median serum total 
triglycerides 1.7 (1.1-2.7) mmol/l. The hormonal profile showed a mean TT of 14.5 ± 
5.8 nmol/l, mean SHBG level of 40.7 ± 20.3 nmol/l, FAI of 40.4 ± 17, FT of 265.9 ± 
 












Table 4 shows the characteristics of the control group. The mean age of the control 
group was 43.9 ± 10.7 years and the mean BMI was 27.11 ± 4.2 kg/m2. Mean 





4.3 Clinical characteristics in the Study Group vs. Control Group 
 
When compared with the Control group, patients with T2DM (Study group) were 
significantly older (57.7 ± 11.1 vs 43.9 ± 10.7 years; p<0.001), had a higher BMI 
(29.8 ± 6 vs 27.1 ± 4.2 kg/m2; p=0.01) but had similar systolic and diastolic blood 











Study Group  
Age (years) 57.5 ± 11.2 
Ethnicity  
African 87 (59%) 
Indian 58 (39%) 
White 3 (2%) 
Diabetes duration (years) 11.4 ± 8.9 
Smoking (current or Ex) 55 (37%)* 
Systolic pressure (mmHg) 136 ± 16.5 
Diastolic pressure (mmHg) 77.3 ± 10.0 
Height (cm) 170.0 ± 0.06 
Weight (kg) 85.9 ± 17.8 
BMI (kg/m2) 29.8 ± 6.0 
Waist (cm) 103.3 ± 12.9 
Waist:hip (WHR) 0.97 ± 0.07 
Results expressed as Mean ± SD or (n) % except where indicated. 








Table 2: Medication history in the study group (n:140) 
 
Medication N % Median dose (IQR) 
Metformin (mg) 100 71.4 1000 (1000-2000) 
Sulphonylurea 44 31.4  
Gliclazide (mg) 31 21.5 160 (40-320) 
Glibenclamide (mg) 13 9.3 12.5 (5-20) 
DPP4i 2 1.4  
Insulin (IU) 78 55.7 58 (0-63) 
Statin 92 65.7  
Fibrate 5 3.6  
Anti-hypertensive 117 83.6  
ACEI/ARB 96 68.6  
Diuretic 83 59.3  
Amlodipine 58 41.4  
Doxazosin 19 13.6  
Beta-blocker 30 21.4  
Aspirin 93 66.4  
DPP4i: dipeptidyl peptidase inhibitor; ACEI: angiotensin converting enzyme inhibitor; 








Table 3: Laboratory results in the study group 
 
Metabolic profile*  
HbA1c (%) 8.6 ± 1.9 
Serum fructosamine (µmol/l) 317.5 ± 71.7 
Serum lipids (mmol/l)  
Total cholesterol 4.2 ± 1.3 
Total triglycerides 1.7 (1.1-2.7) 
HDL cholesterol 1.1 ± 0.3 
LDL cholesterol 2.5 ± 1.41 
Hormonal profile (n:148)  
Serum total testosterone (nmol/l)_ 14.5 ± 5.8 
Serum SHBG (nmol/l) 40.7 ± 20.3 
Free androgen index 40.4 ± 17.0 
Serum free testosterone (pmol/l) 265.9 ± 90.4 
Serum LH (mIU/L) 5.3 (3.8-7.3) 
Mean ± SD or median (IQR) 
*HbA1c (n:145); fructosamine (n:88); lipid profile (n:128) 
HbA1c: Haemoglobin A1c; HDL: high density lipoprotein; LDL: low density lipoprotein; 








Table 4: Clinical and biochemical characteristics in the study group (n:148) compared 




Study group (n:148) 
 





   
Age (years) 57.7 ± 11.1 43.9 ± 10.7 <0.001 
BMI (kg/m2) 29.82 ± 6.0 27.11 ± 4.2 0.011 
Systolic pressure (mmHg) 135.78 ± 16.5 130.86 ± 21.6 0.134 
Diastolic pressure (mmHg) 77.30 ± 10.0 76.39 ± 8.6 0.613 
Biochemical results (serum) 
   
Total testosterone (nmol/l) 14.5 ± 5.8 18.83 ± 7.2 <0.001 
SHBG (nmol/l) 40.7 ± 20.3 42.0 ± 20.0 0.685 
Free androgen Index 40.4 ± 17.0 49.6 ± 19.5 0.002 
Free testosterone (pmol/l) 265.9 ± 90.4 351.7 ± 127.3 <0.001 
LH (IU/L) 5.8 ± 3.1 4.5 ± 2.3 0.006 
Results expressed as Mean ± SD 
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CHAPTER 5: SERUM TOTAL TESTOSTERONE, FREE 
TESTOSTERONE, SEX-HORMONE BINDING GLOBULIN AND FREE 
ANDROGEN INDEX IN THE STUDY POPULATION 
 
5.1 Serum free-testosterone (FT), total testosterone (TT) and sex-hormone 
binding globulin (SHBG) by age group and BMI category in the Study Group 
Mean serum FT, TT and SHBG in the Study group have been discussed in the 
previous chapter (Table 3). Figure 3 shows the serum FT levels across age groups. 
Mean serum FT levels were lower with increasing age; the highest free testosterone 
levels were observed in the youngest group (< 40 years) and the lowest mean FT 
levels were noted in the oldest group (≥70 years). A significant difference (p<0.05) 
was found between the following age groups: <40 yr vs. 40-49 yr; 50-59 yr vs. 60-69 




Figure 4 shows the mean TT, SHBG and FAI values across five age categories. 
SHBG levels were found to be higher with increasing age. Although TT and FAI were 
lower with increasing age, there was no significant difference between age groups. 





Figure 5 demonstrates mean TT levels, SHBG and FAI across BMI categories. The 
lowest TT, SHBG and FAI were noted in the highest BMI category (>40 kg/m2). 
Mean TT in the Study group with BMI >40 kg/m2 was significantly lower when 
compared to patients in all other BMI categories [vs. <25 kg/m2 (p<0.0001); vs. 25- 
29.9 kg/m2 (p<0.0001); vs. 30-39.9 kg/m2 (p<0.05)]. With respect to FT levels, Figure 
 







> 40 kg/m2 category and significantly lower when compared to all other BMI 
categories [vs. <25 kg/m2 (p<0.001); vs. 25-29.9 kg/m2 (p<0.0001); vs. 30-39.9 
kg/m2 (p<0.05)]. Study group participants with a BMI between 30 and 39.99 kg/m2 





5.2 Comparison between Study group and Control group 
 
When compared with the Control group, mean serum TT (14.5 ± 5.8 vs. 18.8 ± 7.2 
nmol/l; p<0.001), FAI (40.4 ± 17.0 vs. 49.6 ± 19.5; p=0.002) and FT (265.9 ± 90.4 vs. 
351.7 ± 127.3 pmol/l; p<0.001) was significantly lower in the Study group (T2DM) 
while mean serum LH level was significantly higher (5.8 ± 3.1 vs 4.5 ± 2.3 IU/L; 




Table 5 shows the prevalence of LSTT and LSFT in the Study group compared with 
the Control group. There was a significantly higher prevalence of LSTT and LSFT in 





Further analysis was performed to determine whether the differences in FT levels 
between study subjects and controls remained significant after adjusting for other 
variables that differed between these groups. Multiple variable logistic regression 
analysis was performed and factors entered into the model included age, BMI, LH 
levels and free androgen index (Table 6). After controlling for these variables, FT 







Table 5: Prevalence of low serum total testosterone (LSTT) and low serum free 




  %(n)  





LSTT 35.8 (53) 16.0 (8) 0.0087 
LSFT 16.2 (24) 2.0 (1) 0.0088 
LSFT: low serum free-testosterone; LSTT: Low serum total-testosterone; * Pearson 







Table 6: Multiple variable logistic regression analysis for independent association of 




  B S.E. Wald df Sig. OR 95% CI for OR 
        Lower Upper 
Step 3a Age .136 .028 23.090 1 .000 1.146 1.084 1.211 
 FAI .064 .022 8.902 1 .003 1.067 1.022 1.113 
 FT -.011 .003 10.193 1 .001 .989 .983 .996 
 LH .220 .120 3.393 1 .065 1.246 .986 1.575 
 Constant -6.081 1.859 10.701 1 .001 .002   
a Variable(s) entered on step 1: Age, BMI, TT, FAI, FT, LH    
BMI: body mass index, FAI: free androgen index, FT: free testosterone, LH: 
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<25 25-29.99 30-39.99 ≥40 
BMI (Kg/m2) 
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CHAPTER 6: PREVALENCE OF ANDROGEN DEFICIENCY 
SYMPTOMS AND AGEING MALE’S SYMPTOM (AMS) SCORE IN 
THE STUDY GROUP 
The majority of the Study group reported a history of erectile dysfunction (58.8%, 
n=87) (Table 7). Loss of libido was also a common symptom, reported in 56.1% 





Regarding the AMS questionnaire score (AMS) in the Study group, the median total 
score was 34 (26.5 - 42), with scores of 8.0 (5 - 11) for the psychological domain, 14 
(11 - 19) for the somatic domain and 12 (9 - 15) for the sexual domain (Table 7). 
Twenty-five percent of patients had an AMS score that was < 27 and not consistent 
with symptoms of low serum testosterone. The overall prevalence of a high AMS 
score (≥ 27) was 74.5% (n=111). Of these, 36.2% (n=54) had a score of between 27 
and 36, consistent with mild symptoms of low serum testosterone; 26.9% (n=40) 
scored between 37 and 49 i.e. moderate symptoms and 11.4% (n=17) scored above 




The prevalence of a high AMS score ≥ 27 varied across age groups. The highest 
prevalence was seen in the 60-69 year age category (83.6%). However, similarly 
high prevalence was also noted in the 40-49 year category (65.4%), 50-59 year age 
category (79.1%) and in 71.4% of patients in the >69 year age category. The lowest 







Table 7: Prevalence of androgen deficiency symptoms in the study group (n:148) 
 
 
Study group (n=148) 
Symptoms on Enquiry n % 
Any symptom 102 68.9 
Erectile dysfunction 87 58.8 
Low libido 83 56.1 
Decrease in beard growth 4 2.7 
Infertility 3 2.0 
AMS questionnaire score*   
Psychological domain 5-11 8.0 
Somatic domain 11-19 14.0 
Sexual domain 9-15 12.0 
Total score 26.5-42 34.0 
High AMS score ≥ 27 111 75.0 
AMS score 27-36 54 36.2 
AMS score 37-49 40 26.9 
AMS score >49 17 11.4 
*Results expressed as Median (IQR) or n (%) 
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CHAPTER 7: PREVALENCE OF LOW SERUM FREE 
TESTOSTERONE (LSFT), LOW SERUM TOTAL TESTOSTERONE 
(LSTT) AND HYPOGONADISM IN THE STUDY GROUP 
Table 8 shows the prevalence of low serum testosterone and hypogonadism in the 
Study group. 
7.1 Prevalence of low serum calculated free testosterone (LSFT) 
 
The prevalence of low serum calculated free-testosterone (LSFT) was 16.2% (n=24) 
(Table 8) and varied across age groups and BMI (Figure 8 and 9). The prevalence 
was higher with age and the highest prevalence was noted in patients >60 years of 
age. The prevalence of LSFT was only 8.7% in the 40-49 year age category and in 
0% of patients < 40 years of age (Figure 8). Figure 9 shows the varying prevalence 
of LSFT across BMI categories with the highest prevalence seen in patients with BMI 
>40 kg/m2 (50%). However, LSFT was also present in the lowest BMI category (<25 




7.2 Prevalence of low serum total testosterone (LSTT) 
 
Using TT as the criterion for low testosterone, the prevalence was variable, 
depending on the serum TT cut-point. The prevalence of LSTT was 35.8% (n=53) 
with a cut-point of <12nmol/l; 10.1% (n=15) with TT values <8nmol/l and 25.7% 
(n=38) for borderline TT (8-12 nmol/l). Using the Endocrine Society clinical guideline 







7.3 Prevalence of Hypogonadism 
 
The prevalence of hypogonadism in the Study group was variable, depending on 
whether FT or TT was used the criterion for defining low serum testosterone (Table 
8). Using FT as the criterion, the prevalence of hypogonadism was 11.5% (n=17). 
When TT < 12 nmol/l was used as the criterion for defining low testosterone, the 
prevalence was 26.3% (n=39). The prevalence of borderline hypogonadism was 
18.9% (n=28) and that of overt hypogonadism was 7.4% (n=11) (Table 8). 
 
The prevalence of primary versus secondary hypogonadism as defined by serum LH 














Definition n % 
Low serum free-testosterone (FT) <180 pmol/l 24 16.2 
Low serum total-testosterone (TT) 
  
<12 nmol/l 53 35.8 
<8 nmol/l 15 10.1 
Borderline 8-12 nmol/l 38 25.7 
Endocrine Society Definition* 28 18.9 
Hypogonadism 
  
FT <180 pmol/l + AMS score ≥ 27 17 11.5 
TT <12 nmol/ + AMS score ≥ 27 39 26.3 
TT 8-12 nmol/ + AMS score ≥ 27** 28 18.9 
TT <8 nmol/l + AMS score ≥ 27† 11 7.4 
 
*Endocrine Society Clinical Practice Guideline definition of low serum testosterone 
(Bhasin et al.; 2010): TT < 8 nmol/l and TT 8-12 nmol/l with FT<180 pmol/l; 
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CHAPTER 8: CLINICAL AND BIOCHEMICAL CHARACTERISTICS 
IN THE STUDY GROUP WITH NORMAL SERUM FREE 
TESTOSTERONE (NSFT) AND LOW SERUM FREE 
TESTOSTERONE (LSFT) AND RISK FACTORS FOR LSFT 
There was no significant difference in the total or individual domain AMS 
questionnaire scores between patients with LSFT and those with NSFT. The 
prevalence of an elevated AMS score (≥ 27) was 70.8% (n=17) in patients with LSFT 




Tables 10 and 11 show the relationship between LSFT and variables including 
demographic, clinical and laboratory variables. Variables that were found to be 
significantly associated with LSFT in univariate analysis (Table 10) included age, 
decrease in beard growth, BMI, waist circumference, hip circumference and albumin 
level. In multivariate logistic regression analysis (Table 11), the significant 
independent risk factors associated with LSFT included age [OR 1.05 (95%CI 1.02- 
1.218), p=0.043)] and waist circumference [OR 1.033 (95%CI 0.999-1.068, 
p=0.059)]. For every increase in age by 1 year, the risk of LSFT was higher by 5%. 





Receiver operating characteristic (ROC) analysis was performed using the model in 
Table 11 to predict the probability of LSFT; the area under the curve (AUC) was 








Table 9: Ageing Males’ Symptom (AMS) score in the study group: patients with normal 



















Somatic domain 11.5 (11-20) 14.0 (11-18) 0.3 
Sexual domain 11.5 (7.5-15) 12.0 (9-15) 0.5 
Total score 36.0 (23-43.5) 34.0 (27-42) 0.9 
 







Results are median (IQR) or % (n)*; AMS score: Ageing Males’ Symptom score; 







Table 10: Clinical risk factors and hormonal characteristics associated with low serum 




 LSFT NSFT OR 95% CI P * 
Demographics      
Age 61.4 ± 10.4 56.8 ± 11.2 1.050 1.004-1.099 0.033 * 
Duration DM 12.0 ± 10.9 11.3 ± 8.6 1.009 0.962-1.058 0.718 
Medical History      
Erectile dysfunction 13 (54.2) 74 (59.2) 1.138 0.463-2.798 0.777 
Loss of Libido 8 (33.3) 75 (60) 2.870 1.132-7.278 0.026 * 
Decreased beard 
growth 
2 (8.3) 2 (1.6) 0.172 0.023-1.290 0.087 * 
Infertility 1 (4.2) 2 (1.6) 0.361 0.031-4.150 0.413 
Retinopathy 8 (33.3) 27 (22) 1.796 0.695-4.644 0.227 
Microalbuminuria 8 (33.3) 26 (21) 1.885 0.727-4.885 0.192 
Proteinuria 7 (29) 20 (16) 2.141 0.786-5.831 0.136 
IHD 3 (13) 23 (19) 0.627 0.172-2.283 0.497 
PVD 3 (13) 8 (6) 2.071 0.508-8.450 0.310 
CVD 2 (8) 4 (3) 2,727 0.471- 
15.808 
0.263 
Smoker (current) 7 (29.2) 24 (19.4) 1.541 0.557-4.26 0.404 
Smoker (ex) 3 (12.5) 21 (16.9) 0.755 0.198-2.877 0.681 
Clinical      
Height 1.7 ± 0.1 1.7 ± 0.1 0.009 0-19.9 0.227 
Weight 90.4 ± 25.3 85 ± 15.9 1.016 0.993-1.040 0.174 
BMI 31.9 ± 8.6 29.4 ± 5.3 1.063 0.994-1.136 0.073 * 




1.035 0.110-1.069 0.041 * 
Hip circumference # 111.0 ± 
14.5 
105.4 ± 8.3 1.048 0.993-1.107 0.086 * 
WHR # 1.0 ± 0.08 0.97 ± 0.07 63.216 0.031- 
12947 
0.286 




0.994 0.968-1.021 0.675 
Diastolic BP 76.1 ± 11.5 77.5 ± 97 0.986 0.943-1.030 0.532 
Laboratory tests      
HbA1c 8.6 ± 1.7 8.6 ± 2.0 1.005 0.797-1.265 0.968 







Triglycerides 1.9 ± 0.9 2.1 ± 1.5 0.893 0.634-1.258 0.517 
HDL-cholesterol 1.1 ± 0.2 1.1 ± 0.3 1.069 0.182-6.278 0.941 
LDL-cholesterol 2.2 ± 1.5 2.2 ± 0.9 1.0 0.645-1.550 0.999 
Haemoglobin 13.2 ± 1.5 13.4 ± 1.7 0.923 0.691-1.231 0.585 
Haematocrit 0.4 ± 0.04 0.4 ± 0.04 0.007 0-288 0.359 
Albumin 42.5 ± 3.5 44.5 ± 4.5 0.902 0.810-1.004 0.058 * 
ALP 109.9 ± 112 90.5 ± 28.8 1.005 0.997-1.013 0.213 




1.003 0.999-1.008 0.203 
ALT 28.7 ± 23.9 31.8 ± 21.9 0.992 0.966-1.019 0.571 
AST 27.6 ± 13.8 25.2 ± 97 1.019 0.978-1.061 0.364 
Metabolic syndrome 22 (92) 105 (85) 1.990 0.432-9.170 0.377 
Results are mean ± SD or n(%); *Significance at 0.1 level; # missing replaced with 
series mean. 
IHD: ischaemic heart disease, PVD: peripheral vascular disease, CVD: 
cerebrovascular disease, BMI: body mass index, BP: blood pressure, ALP: alkaline 
phosphatase, GGT: gammaglutamyl transferase, ALT: alanine transaminase, AST: 
aspartate transaminase, HbA1c: haemoglobin A1c, LDL: low density lipoprotein, HDL: 







Table 11: Multivariate logistic regression analysis for the clinical risk factors and 
hormonal characteristics associated with low serum calculated free testosterone levels 




  B S.E. Wald df Sig. OR 95% CI for OR 
        Lower Upper 
Step 
4a 
Age .049 .024 4.108 1 .043 1.050 1.002 1.100 
 WC .033 .017 3.565 1 .059 1.033 .999 1.068 
 
Constant -8.013 2.402 11.126 1 .001 .000 
  
a. Variable(s) entered on step 1: Albumin, Hip circumference (HC), Age, Body mass index 







Figure 10: Reciever operating characteristics (ROC) curve – model using age and 
waist circumference for predicting low serum free testosterone (LSFT) levels 
 
 
Figure 10. Reciever operating characteristic (ROC) analysis was performed using 
age and waist circumference in a model to predict the probability of low serum free 
testosterone (LSFT). The area under the curve (AUC) was 0.658. The overall 







CHAPTER 9: CLINICAL AND BIOCHEMICAL CHARACTERISTICS 
IN THE STUDY GROUP WITH NORMAL SERUM TOTAL 
TESTOSTERONE (NSTT) AND LOW SERUM TOTAL 
TESTOSTERONE (LSTT) AND RISK FACTORS FOR LSTT 
Table 12 shows the comparison between patients with LSTT and NSTT with respect 
to demographic data, clinical variables, laboratory results and risk factor analysis. 
When compared with NSTT, patients with LSTT had a higher prevalence of 
peripheral vascular disease (PVD) and measures of adiposity. Univariate logistic 
regression analysis found a significant association between LSTT and the presence 
of microalbuminuria, presence of proteinuria, weight, BMI, waist circumference, hip 
circumference and the presence of metabolic syndrome. In multivariate logistic 
regression analysis, the only significant risk factor associated with LSTT was BMI 
[OR 1.138 (95%CI 1.063-1.218), p<0.0001)] (Table 13). For every one unit increase 




ROC analysis was performed using this model to predict the probability of LSTT and 
gave an area under the curve (AUC) of 0.677. The overall percentage of cases 







Table 12: Clinical risk factors and hormonal characteristics associated with low serum 




 LSTT NSTT OR 95% CI P 
Demographics      
Age 58.0 ± 11.7 57.5 ± 11.0 1.008 0.977-1.039 0.615 
Duration DM 11.5 ± 10.2 11.4 ± 8.3 1.002 0.965-1.040 0.906 
 
Medical History 
     
Erectile dysfunction 22.0 (41.5) 59 (62.1) 1.405 0.708-2.786 0.331 
Loss of Libido 20 (37.7) 59 (62.1) 1.912 0.964-3.793 0.064 * 
Decreased beard 
growth 
2 (3.8) 2 (2.1) 0.538 0.074-3.933 0.541 
Infertility 1 (1.9) 2 (2.1) 1.097 0.097-12.391 0.940 
Retinopathy 9 (17) 23 (24.2) 0.916 0.413-2.032 0.830 
Microalbuminuria 11 (20.8) 17 (17.9) 2.167 0.944-4.725 0.052 * 
Proteinuria 9 (71) 13 (13.7) 2.264 0.972-5.275 0.058 * 
IHD 8 (15.1) 15 (15.8) 1.397 0.589-3.311 0.448 
PVD 7 (13.2) 3 (3.2) 5.452 1.380-21.540 0.016 
CVD 2 (3.8) 3 (3.2) 1.840 0.358-9456 0.465 
Smoker 10 (18.9) 21 (22.1) 0.794 0.333-1.890 0.602 
Smoker (ex) 8 (15.1) 15 (15.8) 1.000 0.394-2.504 1.000 
Clinical      
Height 1.7 ± 0.1 1.7 ± 0.1 1.029 0.004-297.4 0.992 
Weight 93.7 ± 21.4 81.5 ± 13.7 1.043 1.020-1.066 <0.001 * 
BMI 32.5 ± 7.4 28.3 ± 4.5 1.138 1.063-1.218 <0.001 * 
Waist 
circumference 
108.5 ± 14.9 100.4 ± 
10.7 
1.053 1.022-1.084 0.001 * 
Hip circumference 
# 
110.7 ± 10.5 103.6 ± 7.7 1.099 0.034-1.168 0.002 * 
WHR # 1.0 ± 0.1 1.0 ± 0.07 17.307 0.039-7620 0.359 
Systolic BP 135.2 ± 15.4 135.9 ± 
17.1 
0.998 0.977-1.018 0.818 
Diastolic BP 77.1 ± 9.3 77.4 ± 10.4 0.998 0.964-1.032 0.885 
Laboratory tests      
HbA1c 8.7 ± 1.8 8.5 ± 2.0 0.031 0.863-1.231 0.738 







Total triglycerides 2.3 ± 1.4 2.0 ± 1.5 1.157 0.916-1.462 0.222 
HDL-cholesterol 1.0 ± 0.2 1.1 ± 0.3 0.506 0.123-2.093 0.347 
LDL-cholesterol 2.3 ± 1.2 2.1 ± 0.9 1.191 0.842-1.687 0.323 
Haemoglobin 13.2 ± 1.6 13.5 ± 1.7 0,890 0.712-1.114 0.309 
Haematocrit 0.4 ± 0.05 0.4 ± 0.04 0.001 0-4.8 0.112 
Albumin 43.6 ± 4.2 44.5 ± 4.4 0.954 0.874-1.041 0.292 
ALP 97.4 ± 79.3 91.8 ± 30 1.002 0.995-1.009 0.599 
GGT 68.1 ± 166.8 52.8 ± 50.1 1.001 0.996-1.005 0.477 
ALT 29.5 ± 20.0 32.3 ± 23.5 0.994 0.975-1.013 0.519 
AST 25.8 ± 11.2 25.5 ± 10.1 1.003 0.967-1.039 0.891 
Metabolic 
syndrome 
49 (92.5) 78 (82.1) 2.670 0.848-8.401 0.093 * 
Results are mean ± SD or n(%); * Significance at 0.1 level; # missing replaced with 
series mean. 
Abbreviations: IHD: ischaemic heart disease, PVD: peripheral vascular disease, 
CVD: cerebrovascular disease, BMI: body mass index, BP: blood pressure, ALP: 
alkaline phosphatase, GGT: gammaglutamyl transferase, ALT: alanine transaminase, 
AST: aspartate transaminase, HbA1c: haemoglobin A1c, LSTT: low serum total 







Table 13: Multivariate logistic regression analysis showing the clinical risk factors and 
hormonal characteristics associated with low serum total testosterone (LSTT) levels in 




 B S.E. Wald df Sig. OR 95% CI for OR 
Lower Upper 
















a. Variable(s) entered on step 1: metabolic syndrome, hip circumference, waist 







Figure 11: Reciever operating characteristics (ROC) curve – model using body mass 
index for predicting low serum total testosterone (LSTT) levels 
 
 
Figure 11. Reciever operating characteristic (ROC) analysis was performed using 
body mass index to predict the probability of low serum total testosterone (LSTT). 
The area under the curve (AUC) was 0.677. The overall percentage of cases 







CHAPTER 10: VALUE OF THE AGEING MALE’S SYMPTOM (AMS) 
QUESTIONNAIRE IN PREDICTING LOW SERUM FREE 
TESTOSTERONE (LSFT) AND LOW SERUM TOTAL 
TESTOSTERONE (LSTT) IN THE STUDY GROUP 
The utility of the AMS questionnaire in predicting LSFT and LSTT was assessed 
using ROC analysis (Figure 12 and 13). None of the individual domains nor the total 
AMS score were a good predictor of either LSFT or LSTT. In both cases, the AUC 
was not significantly better than 0.5 in any of the scores or total score. Sensitivities 
were not calculated due to the poor predictive probability of the questionnaire. There 
was a low correlation between TT and the AMS scores and this was also the case 







Table 14: Pearson correlation between Ageing Males’ Symptoms (AMS) score and 















Pearson Correlation .097 -.007 .154 .087 
Sig. (2-tailed) .243 .930 .062 .295 
 




Pearson Correlation .109 -.104 .018 -.003 
Sig. (2-tailed) .185 .209 .830 .974 
 







Figure 12: ROC curve results for predicting low serum free testosterone (LSFT) using 






Figure 12. Reciever operating characteristic (ROC) analysis was performed using the 
Ageing male’s symptom (AMS) questionnaire to predict the probability of low serum 
free testosterone (LSFT). The area under the curve (AUC) for individual components 







Figure 13: ROC curve results for predicting low serum total testosterone (LSTT) 




Figure 13. Reciever operating characteristic (ROC) analysis was performed using the 
Ageing male’s symptom (AMS) questionnaire to predict the probability of low serum 
total testosterone (LSTT). The area under the curve (AUC) for individual components 







CHAPTER 11: CORRELATION ANALYSIS IN THE STUDY GROUP 
 
The correlation between the hormonal variables (TT, FT, FAI, SHBG) and clinical 
characteristics and metabolic characteristics in the study group are outlined in 




There was a moderate inverse correlation between BMI, waist circumference and 
number of features of the metabolic syndrome with TT (r = -0.34, p<0.001; r=-0.35, 




For FAI, weak correlations were observed with duration of DM, total daily insulin 
dose, WHR and waist circumference. A moderate inverse correlation was also noted 




With respect to FT, there was a weak negative correlation with BMI, WHR and 
number of features of the metabolic syndrome (r= -0.27, p<0.001; r= -0.22, p<0.05; 
r= -0.19, p<0.05) but a moderate inverse correlation with age and waist 
circumference (r= -0.45, p<0.001; r= -0.33, p<0.001). The scatter plot (Figure 14) 













Table 16 shows the correlation between the metabolic and hormonal profile among 
the study subjects. There was a weak inverse correlation between serum 
triglycerides and TT (r = -0.18, p=0.03) but this relationship was not observed with 
FT. A weak inverse correlation was also noted between SHBG and serum 
triglycerides (r= -0.25, p=0.003). For both FT and TT, no significant correlation was 

































Duration of Diabetes -0,06 0,46 -0,16 0,06 0,04 0,6 
Insulin daily dose -0,07 0,4 -0,15 0,08 0,03 0,7 
Body mass index -0,34 < 0.001 -0,27 <0.001 -0,20 0,01 
Waist to hip ratio -0,20 0,1 -0,22 0,04 -0,06 0,6 
Waist circumference -0,35 <0.001 -0,33 <0.001 -0,15 0,1 


































 r p r P r p r p 
HbA1c -0,10 0,2 -0,001 0,9 -0,02 0,78 -0,11 0,2 
Total cholesterol 0,07 0,4 0,07 0,4 0,08 0,37 0,01 0,9 
LDL cholesterol 0,01 0,9 0,05 0,6 0,02 0,80 -0,01 0,9 
HDL cholesterol 0,13 0,1 0,03 0,7 0,10 0,28 0,09 0,3 







Figure 14: Relationship between free-testosterone (FT) and body mass index (BMI) 




















CHAPTER 12: SERUM LUTEINIZING HORMONE (LH) LEVELS IN 
THE STUDY GROUP AND CONTROL GROUP AND BY 
TESTOSTERONE CATEGORIES 
Table 17 shows the mean LH level in the Study group and Control subjects by serum 
testosterone categories. Overall, when compared to control subjects, patients with 
T2DM had a significantly lower mean serum LH level (4.5 ± 2.3 IU/L vs. 5.8 ± 3.1; 
p=0.006). However, the mean LH levels were within the normal reference ranges 




When the Study group was divided into normal and low testosterone categories, 
there was no significant difference in mean LH levels between patients with LSFT vs. 




Among patients with LSTT, in subjects with TT < 8nmol/l, the prevalence of patients 
with high, normal and low LH levels was 26.7% (n=45), 60% (n=9) and 13.3% (n=2), 
respectively (Table 18). In the group with borderline TT (8-12 nmol/l), the proportion 
of patients with high, normal and low LH levels were 15.8% (n=6), 78.9% (n=30) and 




Table 18 shows the distribution of LH in the Study group with low testosterone 
levels. In patients with a LSFT (n=24), 20.8% (n=5) had elevated LH values, 70.8% 







The prevalence of a low or normal LH level (compatible with secondary 
hypogonadism) among patients with LSFT was 79.2% and the remainder (20.8%) 
had elevated LH compatible with primary hypogonadism. The corresponding 
prevalence of a low or normal LH among patients with LSTT (< 12 nmol/l) was 
81.1% and the remainder (18.9%) had elevated LH levels compatible with primary 







Table 17: Serum luteinising hormone (LH) levels in the study group and control group 




Luteinising hormone (IU/L) P 
Study group vs. Control group 
All  0.006 
Study group (n=148) 4.5 ± 2.3  
Control group (n=50) 5.8 ± 3.1  
Study group 
by Total testosterone  0.7 
LSFT group (n=124) 6.1 ± 4.2  
NSFT group (n=24) 5.8 ± 3.9  
by Free testosterone  0.06 
LSTT group (n=95) 5.7 ± 3.7  
NSTT group (n=53) 5.9 ± 2.8  
Results expressed as Mean ± SD. TT: total testosterone; FT: calculated free- 
testosterone; LSFT: low serum free testosterone; NSFT: normal serum free 
testosterone; LSTT: low serum total testosterone; NSTT: normal serum total 







Table 18: Serum luteinising hormone (LH) levels in the study group with low serum 




Testosterone category Luteinising hormone (LH) 
n (%) 
 Low Normal High 
Total testosterone (TT)    
TT < 12 nmol/l (n:53) 4 (7.5) 39 (73.6) 10 (18.9) 
TT < 8 nmol/l (n:15) 2 (13.3) 9 (60) 4 (26.7) 
TT 8-12 nmol/l (n:38) 2 (5.3) 30 (78.9) 6 (15.8) 
 
Free testosterone (FT) 
   
FT <180 pmol/l (n:24) 2 (8.3) 17 (70.8) 5 (20.8) 







CHAPTER 13: DISCUSSION 
 
In this study, in men with T2DM, there was a high prevalence of LSFT <180pmol/l 
(16.2%) and LSTT <12nmol/l (35.8%). Mean serum TT and mean serum FT were 
significantly lower in patients with T2DM compared to control subjects. The overall 
prevalence of androgen deficiency symptoms was 74.5% using the AMS 
questionnaire and 69% on direct patient enquiry, but this difference was not 
significant. Low serum testosterone was not associated with symptoms of androgen 
deficiency and there was a low correlation between AMS scores and both FT and 
TT. LH levels were either normal or low in the majority of patients with LSFT (79.2%) 
or LSTT (73.3%) compatible with hypogonadotropic hypogonadism, with the 




In the Study group, in multivariate analysis, when compared to patients with normal 
serum total testosterone (NSTT), in patients with LSTT there was a significant 
independent negative association only with BMI; an independent negative 
association with age and waist circumference was found in patients with LSFT 




13.1. Prevalence of low serum testosterone 
 
13.1.1 Global prevalence 
 
In this study there was a high prevalence of LSFT (16.2%) and LSTT (35.8%) in men 
with T2DM. The findings of the current study are in accordance with reports from 
cross-sectional studies in western countries such as the United States that showed a 
high prevalence (17-33%) of low serum testosterone in men with diabetes (6,23). A 







reported from India (26.3%), Jordan (36.5%) and Poland (46%) (24–26). The results 
of a large meta-analysis that included cross-sectional data also supports lower 
serum testosterone levels in men with T2DM (11). However it is important to note 
that the reported prevalence may vary between studies depending on the assay 




The prevalence of low serum testosterone has been shown to increase with age in 
the general population (4,9). The current study demonstrated a trend toward 





13.1.2 Sub-Saharan Africa 
 
There is limited data on the prevalence of low serum testosterone in men with T2DM 
from SSA, with only a few studies from Nigeria and a single study each from Ghana 
and South Africa (16–20,27,28). Such studies report the prevalence of LSTT 
between 29.5% and 50%, which is similar to the 35.8% prevalence reported in this 
study (16,17,20,28). From the available studies only four reported the actual 




The only study that is comparable with the current study is the Ghanaian study that 
also measured serum FT. In that study Asare-Anane et al compared FT and TT 
levels in 105 men with T2DM and 105 nondiabetic men (17). Although mean serum 
FT was found to be lower in diabetic compared to control participants (0.2 ± 0.1 vs. 
0.4 ± 0.1 nmol/l, p<0.0001), they did not report on the overall prevalence of LSFT in 







nmol/l in diabetic men in Ghana was much higher, 35.2% and 20%, respectively; 
with the overall prevalence of TT <12 nmol/l of 55.2%. The higher prevalence cannot 
be explained on the basis of age, BMI and diabetes duration of the populations 
being studied. A possible reason is that in the Ghanaian study, recruitment of men 
was purely from a tertiary hospital based diabetes clinic whereas the current study 
included men from a tertiary hospital clinic as well as from a regional hospital based 
clinic. A higher prevalence has also been reported in another teaching hospital 
based study from Nigeria; the prevalence of LSTT < 8 nmol/l with a positive ADAM 





There are five published studies from Nigeria that measured TT with variable assay 
methods and definition for LSTT (18–20,27,28). Only three studies included a control 
group in the study design and reported consistent findings of a lower mean TT level 
among diabetic men compared to control subjects (18,19,27). The report by Akinloye 
et al (19) of extremely low TT levels in diabetic subjects compared with controls (3.1 
± 0.34 vs. 34 ± 3.9 nmol/l; p<0.0001) may have been accounted for by the inclusion 
of patients with newly diagnosed diabetes and concomitant hypertension into the 
study group. Ogbera et al, in a study on 203 Nigerian men with T2DM, reported a 
high prevalence (36%) of testosterone deficiency syndrome defined as a TT 
between 8 and 12 nmol/L with symptoms of hypogonadism or TT <8 nmol/L with or 
without symptoms of hypogonadism (20). Ubajaka et al described a significantly 
lower mean testosterone level in 125 diabetic men compared to 50 non-diabetic 
control subjects attending a university teaching hospital diabetes clinic in Nigeria 
(18). Fabian et al found significantly lower TT among 34 men with T2DM attending a 
university based diabetes clinic in Ibadan, Nigeria when compared to 53 control 







200 men with T2DM attending a diabetes clinic at a teaching hospital in Nigeria, 
Ugwu et al found a 29.5% prevalence of LSTT (defined as <8 nmol/l). The 
prevalence of LSTT < 12nmol/l was 53% which is significantly higher than the 35.8% 
reported in the current study. Compared to the current study, the diabetic men in the 
study by Ugwu et al were similarly aged (57.9 vs. 57.5 yrs), had lower mean waist 
circumference (94.2 vs. 103 cm), shorter duration of diabetes (6.6 vs. 11.4 yrs) and 
these observations do not explain the difference in the prevalence of LSTT with the 
current study (28). However, all the patients in the study by Ugwu et al were sourced 
from a diabetes clinic at a teaching hospital whereas the patients in the current study 




13.1.3 South Africa 
 
There is limited information on the prevalence of low serum testosterone in South 
African men with T2DM. To date, the only published report from South Africa is from 
an academic centre in Pretoria (16). Kemp et al evaluated 150 male subjects with 
diabetes attending a tertiary diabetes clinic at the Steve Biko Academic Hospital; of 
these 91% had T2DM (16). Diabetic men were screened for symptoms of androgen 
deficiency and only serum TT but not FT was measured. The prevalence of LSTT, 
defined as TT below the reference range of 9.9 nmol/l was very high (50%) 
compared to the current study (19%), despite the use of a higher cut-point of <12 
nmol/l for the lower limit of TT in this study. Nevertheless, the overall findings of both 
studies are similar and reflect a high burden of low serum testosterone levels among 
men with T2DM. The higher burden of LSTT among men from the Pretoria study 
may possibly be related to differences in the background characteristics, including 
the mean duration of diabetes, age, waist circumference, cardiovascular disease 
prevalence and statin use. In the Pretoria study, participants were older (62 vs 57.5 







circumference (112 vs 103 cm), higher burden of CVD (41% vs 18%) and a higher 
proportion were on statin therapy (93% vs 66%). Furthermore, there were striking 
differences in the ethnicity of the study groups with the Pretoria study including a 
majority white population (52%) whereas the Durban study included a majority 
African cohort (59%) with only a few white patients (2%). Indian patients formed a 
larger component of the study group in the current study (39%) while only 
contributing to 10% of the study population from Pretoria. Given these differences 
between the two studies, it is likely that the most important factors that explain the 
higher prevalence of LSTT in the Pretoria study is the older age and higher WC, 






There was no significant difference in mean FT levels and prevalence of LSFT 
between African and Indian patients in this study and the number of white patients 
were too few to allow a comparison. Ethnic differences in serum testosterone levels 
have been described in the literature. A recent meta-analysis that included 15 
studies, found that black men have a modest but significant 2.5-4.9% higher FT 
compared to white men; however this difference was not observed for TT (14). It has 
been suggested that ethnic variance may possibly be attributed to differences in 





13.2 Androgen deficiency symptoms and the significance 
 
In this study, androgen deficiency symptoms were assessed by direct enquiry of 
symptoms as well, with the self-administered AMS questionnaire. The overall 







(74.5%) compared to direct patient enquiry (69%), although this difference was not 
significant. There was no significant difference in the prevalence of an AMS score 
≥27 in those with LSFT vs. NSFT (70.8% vs. 75.8%, p=ns). There was a low 




Screening men with T2DM for symptoms of androgen deficiency has been 
recommended by some organisations to justify or determine whether a patient would 
require measurement of serum testosterone levels (29). As noted in the introduction, 
a number of screening tools in the form of self-administered questionnaires have 
been developed but lack sufficient evidence to support their routine use in clinical 
practice. These tools have been developed for the general population but have not 
been specifically validated in diabetic populations. The few available studies in 
diabetic men have shown that the sensitivity of these questionnaires is high but they 
lack specificity; also, that they correlate poorly with serum testosterone (25,30,31). 
Despite this shortcoming, many physicians continue to use these questionnaires in 




The value of using questionnaires for the detection of androgen deficiency 
symptoms and screening for testosterone deficiency in the African setting has not 
been adequately investigated and remains unclear. These tools have been 
developed with data derived from western populations and there is limited 
information on their accuracy and performance in patients from SSA countries. The 
only published data from SSA that investigated the reliability of a screening 
questionnaire was reported from Nigeria (32). This cross-sectional survey on 200 
sub-Saharan African men with T2DM, evaluated the reliability of the Saint Louis 







(44.7%). The authors concluded that the ADAM questionnaire was an unreliable 
marker of testosterone deficiency in their population of men with T2DM. Moreover, 
they identified loss of libido as a reliable marker of testosterone deficiency with better 
accuracy than the ADAM questionnaire. In contrast, the current study did not identify 
any significant association between the symptoms of androgen deficiency on direct 
inquiry and low serum FT or low serum TT levels. Although decreased beard growth 
was found to be associated with LSFT on univariate analysis, this was not significant 
on multivariate analysis. In addition, neither the total AMS score nor its individual 




Similar to the findings in the Nigerian study (32), the South African study from 
Pretoria also found a high prevalence of androgen deficiency symptoms (95%) using 
the ADAM questionnaire with high sensitivity (95%) and very low specificity (5%) 
(16). Sensitivity and specificity of the AMS questionnaire in the current study were 
not calculated due to the poor predictive probability of the score. The current study 
found the AMS questionnaire to be a poor screening tool and was a poor predictor of 
LSTT and LSFT. The lack of a significant difference in AMS scores or prevalence of 
high AMS score between those with LSFT and NSFT, further highlight the weakness 




Based on available data from SSA including two studies from South Africa, there 
appears to be no particular advantage to screening for androgen deficiency 
symptoms using a questionnaire rather than via direct enquiry. Therefore the value 
of both the AMS and ADAM questionnaires in SSA populations remain unresolved 







would be prudent to use the direct symptom enquiry viz. loss of libido, to screen for 




13.3 Prevalence of Hypogonadism 
 
The prevalence of hypogonadism in this study, defined as LSFT in conjunction with a 
positive AMS score, was 11.5%. From available literature, the prevalence of 
hypogonadism using similar criteria reported in western countries ranges from 20- 
42% (23,33). Although the prevalence of low serum testosterone among men with 
T2DM has been reported in several studies from SSA, to date only three studies 
from Nigeria have documented the prevalence of hypogonadism with rates ranging 
from 29.5 to 65.3%, higher than that observed in the current study (19,20,28). The 
likely explanation for this discrepancy is the differences in the definition of 
hypogonadism used in those studies. The study by Akinloye et al reported the 
highest rate of hypogonadism (65.3%) but the definition of hypogonadism that was 
applied was unclear (19). Ogbera et al (20) found a 36% prevalence of 
hypogonadism which was defined as TT < 12nmol/l with associated symptoms of 
hypogonadism which were obtained via direct enquiry and included erectile 
dysfunction, reduced libido, loss of concentration, irritability, hot flushes, reduced 
energy and depression. More recently, Ugwu et al (28) reported that the prevalence 
of overt hypogonadism (defined as TT < 8nmol/l together with a positive ADAM 
score) was 29.5% and that of possible hypogonadism (defined as TT 8-12 nmol/l 
together with a positive ADAM score) was 23%. If these criteria were applied to the 
current study then the corresponding prevalence of overt and possible 
hypogonadism using TT would be 7.4% and 18.9%, respectively. It was not possible 
make a comparison with the single South African study (16) because they did not 










13.4 Aetiology of low serum testosterone levels: role of gonadotropins 
 
It is now well recognized that the majority of diabetic men with low serum 
testosterone have normal or low levels of LH, compatible with hypogonadotropic 
hypogonadism (6,34). The prevalence of normal or low LH among men with low 
serum testosterone is reported to be 67-83% (23,25,35). However, few studies from 
SSA have reported on the role of gonadotropin levels in the aetiology of 




The majority of patients (79.2%) with LSFT in the current study had either normal or 
low LH levels, with only 20.8% having elevated LH levels, compatible with reports 
from other continents (23,25,35). The corresponding rates for LSTT are also similar 
with 73.3% of men with TT <8 mmol/l having a low or normal LH level. Similar 
findings are reported from a Nigerian study (28) with 23.7% of hypogonadal men 
having an elevated FSH or LH level and 76.3% having either normal or low 




The current study found no differences in mean LH levels between LSFT and NSFT 
groups as well as between LSTT and NSTT groups. Limited data from SSA is 
available for comparison. Similar findings were reported by Ugwu et al who found no 
difference in mean LH levels in hypogonadal (TT<8 mmol/l) vs. eugonadal (TT ≥12 




Two studies from SSA compared mean LH and FSH levels in patients with T2DM 







differences in LH in Nigerians (27); by contrast, Asare-anane (17) found that in 
Ghanaians, when compared to control subjects, diabetic men had significantly higher 
mean LH levels, but not FSH levels. This latter finding is similar to the current study 
which also showed that diabetic men had higher LH levels compared to control 
subjects in univariate analysis, though FSH was not measured. It is important to note 
that mean LH levels were within the normal range in all these studies. The most 
likely explanation for the conflicting findings, is that the diabetic subjects in the 
Ghanaian and current study were significantly older than controls and hence more 
likely to have age related decreases in testicular function leading to relatively higher 
gonadotropin levels. This is also supported by results of multivariate analysis 
comparing control subjects to patients with T2DM in the current study which showed 




13.5 Low testosterone and obesity 
 
The association between testosterone and obesity which has been well documented 
(36), is confirmed by the findings of this study. A relationship between serum FT and 
TT with measures of adiposity such as waist circumference, hip circumference, BMI 
and metabolic syndrome was observed. Both FT and TT were inversely correlated 





The significant risk factors associated with LSFT and LSTT in this study were waist 
circumference and BMI, compatible with reports from other studies (39,40). Waist 
circumference but not other measures of adiposity including hip circumference, 
weight, waist-to-hip ratio or BMI was significantly and independently associated with 










Mean BMI in this study was 29.8 kg/m2 with 72% of men being overweight or obese, 
underscoring the importance of measuring FT levels in this high risk population of 
men with diabetes. The observed negative correlation between BMI and SHBG in 
this study confirms the findings in other studies (6). It has been postulated to be the 
reason for the low serum TT in men with diabetes. Although lower SHBG 
concentration related to higher obesity levels among diabetics may partly explain the 
lower TT, they do not account for the lower FT levels. Therefore, other factors such 
as elevated circulating adipokines or higher oestradiol levels which have been 
implicated in the pathogenesis of low serum testosterone in men with obesity, may 





Although there is evidence that obesity and hypogonadism are related, it remains 
speculative as to which of the two conditions is the initiating factor. The prevailing 
hypothesis is that obesity precipitates hypogonadism and this is turn exacerbates 
obesity, leading inexorably to a self-perpetuating vicious circle. The hypogonadal- 
obesity cycle proposed by Cohen infers that accumulation of adipose tissue 
increases expression of aromatase, leading to higher oestradiol levels which inhibits 
gonadotropin releasing hormone (GnRH) and suppresses gonadotropin secretion. 
This ultimately leads to reduced gonadal testosterone secretion with consequent 
further deposition of adipose tissue (42). However, this theory has been challenged 
by a recent study which showed that total and free oestradiol levels are not elevated 
in diabetic men with hypogonadotropic hypogonadism (43). The most favoured 
current postulate is the hypogonadal-obesity-adipocytokine hypothesis (44) which 
implicates the pro-inflammatory adipokines elaborated by adipose tissue depots as 







also be partly responsible for the development of low testosterone in obese men 
(45). High leptin is believed to be consequent to presumed leptin resistance and 
contributes to altered hypothalamic GnRH signaling via kisspeptin, however this 




As in this study, most other studies from SSA have investigated testosterone levels 
in men with diabetes and have found an association with some measure of adiposity. 
A few studies did not include anthropometric measures and one study showed no 
correlation between serum testosterone and the metabolic syndrome parameters 
(20). The consistent finding in the remainder of the studies was that low TT is 
associated with a higher waist circumference (16,19,28) or BMI (17,19) and that TT 
correlated inversely with BMI (17,19) or waist circumference (28). These findings are 
similar to that reported in studies from other parts of the world; although this 
evidence does not confirm causality, it supports the notion that obesity probably 
plays a central role in the pathogenesis of decreased serum testosterone levels in 




Notwithstanding, there are some patients that have low serum testosterone with a 
normal BMI; in this study, 14.8% of patients with a BMI < 25 kg/m2 had LSFT. 
Although a normal BMI in these patients does not exclude the presence of central 
adiposity, it does suggest that other factors than adiposity may also be contributing 
to the development of hypogonadism. For example, insulin resistance though 
strongly associated with T2DM, can occur in normal weight subjects and has been 
shown in some studies to correlate with changes in testosterone (47). Animal models 
support the activity of insulin as a modulator of LH secretion, with lack of insulin 







genetic factors may also be responsible to some degree, for the development of low 
serum testosterone in men with T2DM. Since obesity is strongly linked to the 
development of low testosterone in men with T2DM, it is of particular concern for 
SSA countries that have experienced an increase in obesity prevalence over the 
past decade. More disturbing is that South Africa has the dubious privilege of having 
the highest prevalence of obesity in SSA (49). If this trend continues, many more 





13.6 Relationship with age 
 
The effects of ageing on testosterone levels among men in the general population 
has been extensively investigated and has consistently shown that testosterone 
progressively declines with advancing age. Landmark studies including the 
Massachusetts Male Ageing Study and Baltimore Longitudinal Study on Aging have 
also demonstrated that the prevalence of androgen deficiency increases with ageing 
(4,9). The MMAS study showed that the crude prevalence of testosterone deficiency 




In the current study, serum FT was lower with advancing age. The lowest levels of 
mean FT and mean TT were noted in the oldest age category (>70 years). Age was 
also found to be a significant risk factor associated with LSFT. An inverse correlation 
was observed between age and FT. Therefore, the findings of this study regarding 
the association between LSFT and age are compatible with that reported in the 
general literature. In this study, the relationship with age was further highlighted by 
the absence of LSFT among all patients below the age of 40 years, irrespective of 












The findings in this study also compares well with published findings from other SSA 
countries. Two Nigerian studies reported on the relationship between age and serum 
testosterone in men with T2DM. Akinloye et al (19) showed that there was an 
inverse correlation between age and TT. Although a similar trend was reported in the 
Ghanaian study, this was not statistically significant (17). Ugwu et al demonstrated 
that age was associated with the presence of hypogonadism defined as LSTT with 




In a South African cohort of the Transition and Health during Urbanisation of South 
Africans (THUSA) Study that investigated 364 male subjects between the ages of 20 




Since age is a probable factor that influences serum testosterone levels, it also has 
an important role to play in the selection of diabetic patients for screening of 





13.7 Relationship with glycaemia, lipids and metabolic syndrome 
 
Hypogonadism in men with T2DM has been reported to be associated with morbidity 
which includes lower haematocrit, decreased bone mineral density and insulin 
resistance (51,52). Low serum testosterone has been linked to CVD and mortality in 







effects of low testosterone on men with T2DM, the benefits of testosterone therapy 
on CVD have yet to be confirmed in randomized controlled clinical trials. Small 
studies have shown improvement in insulin resistance with testosterone replacement 
therapy (40). Whether low testosterone in men with T2DM impacts on glycaemic 
control remains unclear; moreover the effects of testosterone treatment on HbA1c still 
remain controversial. A recent meta-analysis showed that testosterone replacement 
treatment did not improve glycaemic control (HbA1c) in men with type 2 diabetes 




In this study, no association was found between serum testosterone (FT and TT) 
and HbA1c and there was no correlation between HbA1c and serum testosterone. 





With respect to serum lipids, no association was noted between serum testosterone 
(FT and TT) and total cholesterol, LDL-cholesterol, HDL-cholesterol and total 
triglycerides. However, the finding of a weak inverse correlation between serum TT 
and serum total triglycerides, is similar to two other studies from SSA and requires 




The number of components of the metabolic syndrome also correlated with serum 
FT and TT. This relationship between metabolic syndrome and low serum 
testosterone in men with T2DM was also observed with one other study from Nigeria 
(19) and has been well described in the literature (56–58). Moreover, in this study 
waist circumference was the best measure of adiposity for predicting LSFT. 







and features of the metabolic syndrome occurs with waist circumference which is a 




In this study, no association was found between low serum testosterone and a 
history of CVD. However, the study was not designed to investigate this relationship 




13.8 Evidence for testosterone screening recommendations 
 
Current international guidelines recommend screening men with T2DM for low 
testosterone (5). There are no national South African policy documents to guide 
healthcare practitioners managing men with T2DM regarding screening this high risk 
population for androgen deficiency. However, the 2017 South African guideline 
document for the management of T2DM published recently by the Society for 
Endocrinology Metabolism and Diabetes of South Africa (SEMDSA), states that 
screening for low serum testosterone levels among men with T2DM and symptoms 
of hypogonadism is mandatory (29). Taken collectively, the available evidence from 
SSA countries including data from two South African centres, indicate a high 
prevalence of low serum testosterone and therefore deserve mention in future 
guidelines from these regions. However, given that most SSA countries are low- 
income regions, it is imperative that the cost-benefit ratio of screening be taken into 




What appears obvious from the two South African studies is that the majority of men 
with T2DM suffer from symptoms of androgen deficiency. However, the ADAM 







Durban (current) study were found to be inaccurate in detecting low serum 
testosterone because of their low specificity or poor predictive capability. This 
highlights the need for studies to validate the use of these questionnaires in 
screening for androgen deficiency among men with T2DM. In the interim, if South 
African men are to be questioned about symptoms of androgen deficiency, then 
asking about erectile dysfunction and loss of libido must be considered first, since 




More national data are required before recommendations can be made regarding a 
universal screening policy for all South African men with diabetes. However, from the 
available evidence it appears that screening for androgen deficiency could be 
justified in this high risk population. Men most likely to benefit from screening for low 
testosterone would be older and overweight with predominant central adiposity. The 
findings from this study do not support screening men younger than 40 years of age. 
Although the exact age cutoff to implement routine screening of serum testosterone 
levels in men with T2DM is unclear, the value of routinely measuring serum 





13.9 Study Strengths 
 
The study was conducted at two centres and included men from the outpatient 
diabetes clinic at a district level and tertiary hospital. All the available research from 
SSA have been single centre studies, usually from an academic institute. Therefore, 
the findings of this study are significant and more representative of the typical 
diabetic male patient managed at an outpatient diabetes clinic. This study was able 







accurate reflection of testosterone status than TT, only one other study from SSA 
data reported the prevalence of LSFT in men with T2DM. A detailed history was 
obtained from all study subjects, allowing the potential effects of pharmacotherapy 
and smoking on serum testosterone to be considered. This is only the second study 
from South Africa to report on the prevalence of low serum testosterone in men with 
T2DM. Few studies have evaluated the value of the AMS questionnaire in men with 
T2DM and the data from this study adds to the literature. No other study from SSA 




13.10 Study Limitations 
 
One of the major limitations was the cross-sectional study design, which does not 
allow for examination of predictive risk factors, only risk association. A prospective 
study may have been able to clarify the association of low serum testosterone with 
CVD and mortality in South African men with T2DM. The sample size could have 
been larger in this study. This research did not include investigation of the effects of 
testosterone treatment in the study design. This study did not evaluate the possible 
effect of socio-economic status on serum testosterone levels. The findings of this 
study may not be extrapolated to all provinces, since it was not representative of all 









In this group of predominantly African and Indian men with type 2 diabetes mellitus 
(T2DM) from KwaZulu-Natal, the prevalence of low serum total and free-testosterone 
was high, and is in accordance with that reported in the literature. Low serum total 
testosterone (LSTT) was associated with a higher body mass index and older age. 
Waist circumference was a significant risk factor associated with low serum free- 
testosterone (LSFT) among men with diabetes. LSFT correlated with age, body 
mass index, waist circumference, waist-to-hip ratio and the number of components 
of the metabolic syndrome. There was no correlation between serum testosterone 
and HbA1c. Men with T2DM had lower serum free-testosterone levels than control 
subjects after correction for age and body mass index. 
Using the Ageing Male’s Symptom Scale (AMS) questionnaire, there was a high 
prevalence of androgen deficiency symptoms which was noted across all age 
groups. However, low serum testosterone was not associated with symptoms of 
androgen deficiency in this study. The AMS questionnaire performed poorly in this 
population and was found to be a poor predictor of low serum total and free- 
testosterone. The poor correlation between serum testosterone (total and free) and 
the AMS score also underscores the weakness of the questionnaire in this 
population. Furthermore, there was no significant difference between the prevalence 
of symptoms on direct enquiry compared to the AMS questionnaire. The most 
frequent symptoms on direct enquiry were erectile dysfunction and loss of libido. 
The aetiology of low serum testosterone in this study is thought to be multifactorial. A 
small percentage of patients had elevated luteinizing hormone levels compatible with 
a primary testicular aberration. In keeping with the prevailing hypothesis however, 
the most likely cause of androgen deficiency was thought to be due to a defect in the 
hypothalamic-pituitary axis, since the majority of patients had a low or normal 







Given the available data from South Africa demonstrating a high prevalence of low 
serum testosterone levels in men with T2DM and that suitable therapy is available, 
screening is justifiable in this population. However, more research is required locally 




13.12 Implications for Practice 
 
Healthcare professionals must have a greater awareness of possible androgen 
deficiency in men with T2DM. Symptoms of androgen deficiency can be sought by 
direct patient enquiry or via a standardized questionnaire. Screening for low serum 
testosterone should be considered in this population if the resources are available. 
Selecting patients for screening based on risk factors such as men who are older or 
obese, in particular those with central adiposity, may increase the yield. Routine 




13.13 Implications for Research 
 
More research is required from other provinces in South Africa to confirm the 
findings of this study and allow a better understanding of the underlying risk factors 
that may be associated with low serum testosterone. This will assist in developing 
more appropriate local guidelines for screening in the South African context. 
Specifically, more data is required to determine the most appropriate clinical 
circumstances that should prompt screening. With the burgeoning cost of health- 
care in South Africa, it is imperative that the cost of screening be justified. Therefore 
research into the cost-benefit ratio of screening is required to determine its value in 
resource poor settings. In addition there is also a dire need for more data from other 
SSA countries. The validity of standardized questionnaires in screening for androgen 







research would stimulate a longitudinal study in South Africa to determine if low 
serum testosterone levels are associated with cardiovascular disease or mortality 
and whether appropriate therapy with testosterone can improve glycaemic control 













 PREVALENCE OF LOW TESTOSTERONE LEVELS IN T2DM STUDY  
  Data Sheet/Questionaire (Interviewer Administered)   
          
Subject Source : IALCH PCHC  Date of completion :    
     Study No:    
DEMOGRAPHICS        
Ethnicity     Endo Number   
Date of Birth    Duration of diabetes    
Age  Current Diagnosis  Using any insulin therapy YES NO  
          
SYMPTOMS    PAST MEDICAL HISTORY    
Erectile Dysfunction YES NO  Testosterone deficiency YES NO  
Loss of Libido YES NO  Past treatment with testosterone YES NO  
Poor Beard growth YES NO  Past exposure to anabolic steroids YES NO  
Infertility  YES NO  Radiotherapy YES NO  
     Chemotherapy YES NO  
DIABETES COMPLICATIONS  Testicular torsion YES NO  
Any Retinopathy YES NO  Orchidopexy or orchidectomy YES NO  
Microalbumiuria YES NO  Previous orchitis eg mumps or TB YES NO  
Proteinuria YES NO  Trauma to testes eg crush injury YES NO  
Ischaemic Heart Dx YES NO  History of Head trauma YES NO  
Peripheral Vasc Dx YES NO  Neurosurgery to pituitary fossa YES NO  
CVA or TIA YES NO  HIV / AIDS YES NO  
          
CHRONIC DISEASE and DRUG HISTORY     
Hypertension YES NO  Specify drug(s):    
Depression YES NO  Specify drug(s):    
Parkinsons YES NO  Specify drug(s)    
Recreational drugs YES NO  Specify: eg. ROH, cocaine, dagga    
Other chronic drugs YES NO  Specify:     
          
CLINICAL         
(a) Height (cm)    (g) Gynaecomastia YES NO  
(b) Weight (kg)    (h) Decreased beard growth YES NO  
(c) Body mass index        
(d) Waist circumferen.    (i) Testicular volume (mls)   
(e) Hip circumference    (use prader orchidometer)  
(f) Waist:Hip ratio    (j) Blood pressure (mmHg)    
          
BLOOD RESULTS        
Total Testosterone   Total Protein   
FSH    Albumin    
LH    Alkaline phosphatase   
Prolactin    G-glutamyl transferase   
Total cholesterol   Alanine transaminase   
Triglycerides   Aspartate Transaminase   
HDL cholesterol   Haemoglobin   
LDL cholesterol   Haematocrit   
     HbA1c    
free Testosterone    Fructosamine   







Appendix 2: AMS Questionnaire (English) 
 
 HOSPITAL No:        STUDY No:        
           
   Ageing Male's Symptom Questionaire    
 Which of the following symptoms apply to you ? Please mark the appropriate box.   
          Extremely 
 SYMPTOMS    None Mild Moderate Severe Severe 
     Score 1 2 3 4 5 
           
1 Decline in your feeling of general well-being      
 (general state of health, subjective feeling)       
2 Joint pain and muscular ache (lower back pain,      
 joint pain, pain in a limb, general back ache)       
3 Excessive sweating (unexpected/sudden episodes      
 of sweating, hot flushes independent of strain)      
4 Sleep problems (difficulty in falling asleep, difficulty      
 in sleeping through, waking up early and feeling tired,      
 poor sleep, sleeplessness)        
5 Increased need for sleep, often feeling tired      
           
6 Irritability         
 easily upset about little things, moody)       
7 Nervousness         
 (inner tension, restlessness, feeling fidgety)       
8 Anxiety (feeling panicky)        
           
9 Physical exhaustion / lacking vitality       
 (general decrease in performance, reduced activity,      
 lacking interest in leisure activities, feeling of getting      
 less done, achieving less, force oneself to undertake activities)     
           
10 Decrease in muscular strength        
 (feeling of weakness)         
11 Depressive mood         
 (feeling down, sad, on the verge of tears, lack      
 of drive, mood swings, feeling nothing is of any use)      
12 Feeling that you have passed your peak       
           
13 Feeling burnt out, having hit rock-bottom       
           
14 Decrease in beard growth        
           
15 Decrease in ability/frequency to perform sexually      
           
16 Decrease in the number of morning erections      
           
17 Decrease in sexual desire/libido        
 (lacking pleasure in sex,        







Appendix 3: AMS Questionnaire (Zulu) 
 
Imibuzo ngezimpawu ezikhombisa ukukhula (ubudala) komuntu wesilisa 
AMS Questionaire 
Phakathi kwalezi zimpawu ezilandelayo yiziphi onazo njengamanje? 
Uyacelwa ukuba ukhethe ibhokisi elilodwa ngophawu onalo/izinkomba onazo. 
Uma zingengo lezozimpawu emzimbeni wakho bhala “akwenzeki” 





Umphumela = 1 2 3 4 5 
1. Ukungazizwa kahle (ngokwempilo)      
2. Ubuhlungu kwamajoyinti nezicubu 
zomzimba (ubuhlungu beqolo, kwamajoyinti 
kwezimbambo, ubuhlungu komhlane 
     
3. Ukujuluka ngokweqile (okujuluka 
okuqhamuka ungalindele, ukuba nezikhawu 
zokushiselwa kakhulu) 
     
4. Inkinga yokungalali (ukungafiki 
kobuthongo, ukungakwazi ukulala ubusuku 
bonke, ukusheshe uvuke uzizwe ukhathele, 
ukulala kabi, ukungalali nhlobo) 
     
5. Ukuzizwa udinga ukulala, ukuhlezi 
uzizwa ukhathele 
     
6. Ukubanenhliziyo encane (ube nolaka, 
ucasulwe yizinto ezincane, ungaqondakali - 
uhleke manje usheshe udinwe 
     
7. Ukwesaba (ukungakhululeki emoyeni, 
ukungabi nasinqe, uxhamazele) 
     
8. Ukutatazela (uzizwe wesaba)      
9. Uzizwe ukhathele / ungenawo 
umdlandla (ukwehla kothando lokwenza izinto 
ezithile ezisebenzisa umzimba, ungabi nothando 
lokuvocavoca umzimba, ukwenqena, ufise 
ukwenza izinto ezincane, ukuziphoqa uma kufanele 
wenze izinto ezizosebenzisa umzimba) 
     
10. Ukwehla kwezicubu / amamasela 
(uzizwe ungenawo amandla) 
     
11. Ubenomuzwa wokungakhululeki 
emqondweni (uzizwe uphansi, uphatheke kabi, 
ufisa ukukhala, ungenawo umdlandla, ube neconsi, 
ube nomuzwa wokuthi ayikho into ewusizo 
empilweni) 
     
12. Uzwe ukuthi awusenawo umdlandla 
owawunawo esikhathini esedlule 
     
13. Uzwe ukuthi sewenele yizinto 
ezenzekayo, awusakwazi ukubekezela 
     
14. Ukungakhuli kwentshebe      
15. Ukwehla kwezinga lokukwazi ukwenza 
ucansi/ ukwehla kwezikhathi owenza 
ngazo ucansi 
     
16. Ukwehla kwamanani okuvuka 
kwenduku ekuseni 
     
17. Ukwehla kwezinga lokufisa ukwenza 
ucansi / lokuhalela ucansi (ukungajabuli 
uma wenza ucansi,ukungafisi ukwenza 
ucansi) 


















CONSENT TO PARTICIPATE IN A STUDY 
 
 
I  have been informed about the study entitled 
“Prevalence of low testosterone levels in a cohort of South African men with type 
2 diabetes attending an outpatient diabetes clinic” by Dr Imran M. Paruk. 
I understand the purpose and procedures of the study. I have been given an 
opportunity to answer questions about the study and have had answers to my 
satisfaction. 
I declare that my participation in this study is entirely voluntary and that I may 
withdraw at any time without affecting any treatment or care that I would usually 
be entitled to. 
If I have any further questions/concerns or queries related to the study I understand 
that I may contact the researcher at the Diabetes Clinic in Inkosi Albert Luthuli 
Hospital. (Telephone number : 031-2401299). 
If I have any questions or concerns about my rights as a study participant, or if I am 
concerned about an aspect of the study or the researchers then I may contact: 
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